Biopharma & Vaccines
Baseimmune is a discovery stage biotech company developing future-proof antigens for universal vaccines. Baseimmune generates artificial cross protective antigens compatible with any delivery systems such as mRNA, viral vectors.
Visit company site
Ariane Gomes
Chief Scientific Officer & Co-Founder
Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics based on a unique, patent protected, discovery platform.
Visit company site
Theodora Harold
CEO
Elasmogen develops innovative antibody-like drugs called soloMERs for the treatment of autoimmune inflammatory diseases and cancer.
Visit company site
Dr Caroline Barelle
CEO
Epitopea are looking to generate therapeutic off-the-shelf cancer vaccines repurposing the mRNA technology that came to prominence in the COVID pandemic, using a new class of tumour-specific antigens.
Visit company site
Dr Jon Moore
CEO
Infex acquires, develops and in-licenses innovative therapeutic solutions to the international threat from antimicrobial resistance, and other pandemic infections.
Visit company site
Carl Curran
Business Development Manager
Developing novel therapies for the treatment and early detection of autoimmune disease with a lead product in type 1 diabetes.
Visit company site
Nara Daubeney
COO & Co-Founder
Developing proprietary technology leveraging biomimicry and evidence-based medicine to empower health care professionals to treat patients with chronic wounds.
Visit company site
Sam Bakri
CEO
A specialist respiratory biotech developing and investigating inhaled IFN-β (SNG001) in late-stage clinical trials for the treatment or prevention of severe viral lung infections.
Visit company site
Richard Marsden
CEO
Category Winners
See our 2023 Category Winners
Meet our 6 Category Winners selected for being market leading
UK Innovators in life sciences.
